Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Restructuring Expands Shedlarz' Responsibilities As Katen Departs

This article was originally published in The Pink Sheet Daily

Executive Summary

New CEO Jeffrey Kindler also establishes a seven member "Executive Leadership Team."

You may also be interested in...



Pfizer’s Shedlarz To Retire By Year End

Departure of Shedlarz follows several other high-profile exits since CEO Kindler took the helm last year.

Pfizer’s Shedlarz To Retire By Year End

Departure of Shedlarz follows several other high-profile exits since CEO Kindler took the helm last year.

Two Pfizer Veterans To Leave Firm

R&D head LaMattina and CFO Levin have 50 years of experience with Pfizer between them.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel